New scan could spot prostate cancer spread better than current test
NCT ID NCT07635524
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a new radioactive imaging agent, 61Cu-NU101, can detect prostate cancer spread as well as or better than the current standard, Pylarify. 34 men with confirmed prostate cancer and visible disease on a prior Pylarify scan will receive one dose of 61Cu-NU101 followed by PET/CT imaging. The study compares the two scans to see if the new agent finds more or different cancer spots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
61Cu-NU101 (a radioactive imaging agent)
What this could lead to
If successful, this could provide a new, equally effective or better imaging option for detecting prostate cancer spread.
What could go wrong
This is a small, early-phase study (34 people) comparing two scans, not a treatment. It may not show a meaningful improvement over the current standard.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hoag Family Cancer Institute
Newport Beach, California, 92663, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington Univeristy School of Medicine
St Louis, Missouri, 63110, United States
Contact